David A. Siegel Bria Cell Therapeutics Corp. Transaction History

Two Sigma Advisers, LP

  • $42.5 Billion
  • Q1 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021
SELL
$4.4 - $9.28 $74,360 - $156,832
-16,900 Closed
0 $0
Q2 2021

Aug 16, 2021
BUY
$2.89 - $6.57 $48,841 - $111,033
16,900 New
16,900 $90,000

Others Institutions Holding BCTX

# of Institutions
2
Shares Held
13
Call Options Held
0
Put Options Held
0
View Full List

About BriaCell Therapeutics Corp.

BCTX Quotes by TradingView
  • Ticker BCTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,518,000
  • Market Cap $15.7M
  • Description
  • BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and...
More about BCTX
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email